DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Oxymorphone

Oxymorphone

  • (Oxycontin®) and Oxymorphone (Opana® ER) Reference Number: ERX.NSST.17 Effective Date: 06/15 Revision Log Last Review Date: 09/16

    (Oxycontin®) and Oxymorphone (Opana® ER) Reference Number: ERX.NSST.17 Effective Date: 06/15 Revision Log Last Review Date: 09/16

  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G

    Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G

  • Heterodimerization of Μ and Δ Opioid Receptors: a Role in Opiate Synergy

    Heterodimerization of Μ and Δ Opioid Receptors: a Role in Opiate Synergy

  • Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity

    Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity

  • Metabolism Data for Common Medications

    Metabolism Data for Common Medications

  • Summary of Synthetic Opioid Testing Within the Department of Defense

    Summary of Synthetic Opioid Testing Within the Department of Defense

  • Hydromorphone Hydrochloride) C-II

    Hydromorphone Hydrochloride) C-II

  • Summary Report of Benefit-Risk Assessment NALDEBAIN

    Summary Report of Benefit-Risk Assessment NALDEBAIN

  • Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review

    Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review

  • Lessons Learned from Precipitated Withdrawal After Early Buprenorphine Initiation After Methadone Elaine Rigney MD, Timothy Wiegand MD

    Lessons Learned from Precipitated Withdrawal After Early Buprenorphine Initiation After Methadone Elaine Rigney MD, Timothy Wiegand MD

  • Stembook 2018.Pdf

    Stembook 2018.Pdf

  • ER-LA FDA REMS Modification Review, April 12, 2015

    ER-LA FDA REMS Modification Review, April 12, 2015

  • Health Alert Movement 2019: Detroit Electronic Music Festival Hart Plaza Downtown Detroit May 25-28, 2019

    Health Alert Movement 2019: Detroit Electronic Music Festival Hart Plaza Downtown Detroit May 25-28, 2019

  • Opioid Peptides: Medicinal Chemistry, 69

    Opioid Peptides: Medicinal Chemistry, 69

  • Martin Dod Drug Testing Update February 2013 DTAB

    Martin Dod Drug Testing Update February 2013 DTAB

  • Interpretation of Opiate Urine Drug Screens

    Interpretation of Opiate Urine Drug Screens

  • Oxycodone and Hydrocodone: Detection in Urine, Oral Fluid, and Blood

    Oxycodone and Hydrocodone: Detection in Urine, Oral Fluid, and Blood

  • Opioid Opt-Out Form Patient Guide

    Opioid Opt-Out Form Patient Guide

Top View
  • Onset, Peak, and Duration of Common Pain Medications Table
  • Page 1 OPANA® ER (Oxymorphone Hydrochloride)
  • Opioid Receptor Agonist with Reduced Constipation in Mice
  • Opioid Receptor Binding, Signaling and Antinociceptive Activity
  • Advances in Achieving Opioid Analgesia Without Side Effects
  • Fentanyl Buccal Tablet
  • CDC Opioid Oral Morphine Equivalent Conversion Factors
  • Is It Noroxymorphone Or Nornaloxone, and Why Should You Care? Stephanie J. Marin , Gwendolyn A. Mcmillin , Frederick G. Strathma
  • Commonly Used Long-Acting Opioids Chart
  • Fentanyl and Fentanyl Analogs
  • A Reference Source for Analgesia & Analgesics in Animals, AWIC Series
  • March 4, 2002 Prior Approval Criteria Amended Date: March 1, 2021 Opioid Analgesics
  • Opioid-Ketamine and Norketamine Codrug Combinations for Pain Management Joseph R
  • Oral and Intravenous Oxymorphone: Relative Potency Compared to Other Μ Opioid Agonists in Humans
  • Opioids and Their Complicated Receptor Complexes Bryen A
  • & Preferred Lab Partners Opioid Interpretation Aids
  • NALBUPHINE HYDROCHLORIDE (Trade Name: Nubain®) December 2019
  • (Hydromorphone), Opana IR (Oxymorphone) ______


© 2024 Docslib.org    Feedback